Application of nedaplatin and paclitaxel in the concurrent radiochemotherapy of cervical carcinoma
10.7619/jcmp.201407029
- VernacularTitle:奈达铂联合紫杉醇在宫颈癌同步放化疗中的应用
- Author:
Jingyi ZHANG
1
;
Yongsheng HU
;
Hongjun ZHANG
;
Xi WANG
;
Guobing SHI
Author Information
1. 沈阳军区总医院 药剂科
- Keywords:
cervical carcinoma;
nedaplatin;
paclitaxel;
concurrent radiochemotherapy
- From:
Journal of Clinical Medicine in Practice
2014;(7):88-90
- CountryChina
- Language:Chinese
-
Abstract:
Objective To study the clinical efficacy of nedaplatin and paclitaxel in patients with cervical carcinom by concurrent radiochemotherapy.Methods A total of 64 patients were ran-domly divided into control group given radiotherapy and observation group added with nedaplatin and paclitaxel with 32 patients in each group.The clinical efficacy and adverse reactions in both groups were evaluated after treatment.Results The clinical efficacy of control group was 65.6%which was lower than that of observation group (75.0%),the difference was not significant.How-ever,the rate of adverse reactions,the overall survival (OS)and the distant metastasis-free survival (DMF)were higher in observation group than that in the control group.Conclusion Concurrent radiochemotherapy with treatment of nedaplatin and paclitaxel is remarkably efficient with low toxi-city in treating cervical carcinoma,so it is worthy of being further studied and promoted in clinic.
